Joel Greenbowe

Joel Greenbowe

UNVERIFIED PROFILE

Are you Joel Greenbowe?   Register this Author

Register author
Joel Greenbowe

Joel Greenbowe

Publications by authors named "Joel Greenbowe"

Are you Joel Greenbowe?   Register this Author

16Publications

977Reads

49Profile Views

Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.

Clin Lung Cancer 2016 11 8;17(6):517-522.e3. Epub 2016 Jun 8.

Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.017DOI Listing
November 2016

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Lung Cancer 2015 May 12;88(2):231-4. Epub 2015 Feb 12.

USC Norris Comprehensive Cancer Center and Hospital, Department of Medicine, Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.02.005DOI Listing
May 2015

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

J Thorac Oncol 2014 Dec;9(12):1821-5

*Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000368DOI Listing
December 2014